CCM
SPRO icon

CAAS Capital Management’s Spero Therapeutics SPRO Stock Holding History

CAAS Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-78,509
Closed -$1.52M – 1375
2020
Q4 		$1.52M Buy
+78,509
New +$1.22M 0.01% 544

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

CAAS Capital Management's SPRO Position: Q1 2021 in Review

CAAS Capital Management sold out of Spero Therapeutics (SPRO) in Q1 2021, closing a stake of 78,509 shares — an estimated $1.52M sold.

CAAS Capital Management first reported a position in SPRO in Q4 2020 and held it in 1 quarter. The position peaked at $1.52M in Q4 2020. 94 funds tracked by Wall St. Rank hold SPRO as of Q1 2021.

  • CAAS Capital Management reported no remaining Spero Therapeutics position as of Q1 2021 after selling out during the quarter.
  • CAAS Capital Management sold 78,509 Spero Therapeutics shares in Q1 2021, an estimated $1.52M.
  • CAAS Capital Management first reported a position in Spero Therapeutics in Q4 2020 and held it in 1 quarter.
  • CAAS Capital Management's Spero Therapeutics position peaked at $1.52M in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2021.

Based on CAAS Capital Management's 13F filing for Q1 2021, filed 17 May 2021.